Regen BioPharma Inc (RGBP)

[Carter]

A team of Research Scientists in Europe, no connections with Regen BioPharma - analyzed receptor NR2F6 - for which Regen has many patents.

Their conclusion: "Nr2f6 thereapies "resulting in striking anti-tumor effects in different advanced mouse models relevant to human cancer."

Quote:
According to all our preclinical data, high NR2F6 expression is likely to critically contribute to the immune-suppressed state of tumor antigen-specific TILs, thus limiting the host’s anti-tumor immune response. Absence of NR2F6, either through genetic ablation in Nr2f6 knockout mice or by the means of siRNA knockdowns, increases the immune system’s ability to mount effective immune responses, resulting in striking anti-tumor effects in different advanced mouse models relevant to human cancer.
https://www.nature.com/articles/s41467-018-04004-2



Affiliations
Division of Translational Cell Genetics, Medical University of Innsbruck, 6020, Innsbruck, Austria

Victoria Klepsch, Natascha Hermann-Kleiter, Patricia Do-Dinh, Bojana Jakic & Gottfried Baier

Pathology of the University Hospital Schleswig-Holstein, Campus Luebeck and Research Center Borstel, Leibniz Lung Center, 23538, Leubeck, Germany

Anne Offermann & Sven Perner

Biocenter, Division of Bioinformatics, Medical University of Innsbruck, 6030, Innsbruck, Austria

Mirjana Efremova, Dietmar Rieder & Anne Krogsdam

Tumor Immunology, Tyrolean Cancer Institute & Internal Medicine V, 6020, Innsbruck, Austria

Sieghart Sopper, Gabriele Gamerith, Zlatko Trajanoski & Dominik Wolf

Department of Pathology, University of Basel, University Hospital Basel, 4031, Basel, Switzerland

Alexandar Tzankov

Medical Clinic III, Oncology, Hematology & Rheumatology, University Clinic Bonn, 53127, Bonn, Germany

Dominik Wolf